Cargando…
Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for th...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387281/ https://www.ncbi.nlm.nih.gov/pubmed/18516312 |
_version_ | 1782155304849375232 |
---|---|
author | McMurray, James G Feldman, Robert A Auerbach, Stephen M DeRiesthal, Herb Wilson, Neal |
author_facet | McMurray, James G Feldman, Robert A Auerbach, Stephen M DeRiesthal, Herb Wilson, Neal |
author_sort | McMurray, James G |
collection | PubMed |
description | Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of flexible doses (25, 50, and 100 mg sildenafil) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insufficient response. At each yearly assessment, more than 94% of participants responded affirmatively to the questions: “Are you satisfied with the effect of treatment on your erections?” and “If yes, has treatment improved your ability to engage in sexual activity?” These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, flexible-dose sildenafil treatment of men with ED. |
format | Text |
id | pubmed-2387281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-23872812008-05-30 Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction McMurray, James G Feldman, Robert A Auerbach, Stephen M DeRiesthal, Herb Wilson, Neal Ther Clin Risk Manag Original Research Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of flexible doses (25, 50, and 100 mg sildenafil) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insufficient response. At each yearly assessment, more than 94% of participants responded affirmatively to the questions: “Are you satisfied with the effect of treatment on your erections?” and “If yes, has treatment improved your ability to engage in sexual activity?” These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, flexible-dose sildenafil treatment of men with ED. Dove Medical Press 2007-12 2007-12 /pmc/articles/PMC2387281/ /pubmed/18516312 Text en © 2007 Dove Medical Press Limited. All rights reserved |
spellingShingle | Original Research McMurray, James G Feldman, Robert A Auerbach, Stephen M DeRiesthal, Herb Wilson, Neal Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
title | Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
title_full | Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
title_fullStr | Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
title_full_unstemmed | Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
title_short | Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
title_sort | long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387281/ https://www.ncbi.nlm.nih.gov/pubmed/18516312 |
work_keys_str_mv | AT mcmurrayjamesg longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction AT feldmanroberta longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction AT auerbachstephenm longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction AT deriesthalherb longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction AT wilsonneal longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction AT longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction |